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Abstract 
New technologies in both reversible contraception and sterilisation are described. 
The review includes recent advances in the development of oral contraception, 
emergency contraception, injectables, vaginal rings, subdermal implants, transdermal 
contraception, intrauterine devices, spermicides and barrier methods. It also covers 
methods of transcervical female sterilisation and more easily reversible male 
sterilisation. The emphasis is on the technology and its safety and effectiveness. 
Hormonal delivery systems are described in some detail. Mention is also made of 
research into vaccines and male hormonal methods, where progress has been 
disappointing.  
 
 
Context 
Technology is of limited value unless governments can supply their populations with 
contraceptive services and supplies. In many developing countries, individuals and 
couples who cannot afford to purchase contraceptives do not enjoy the human right 
to decide on the number and spacing of their children. More than 200 million women 
in the developing world are not using any form of contraception or using traditional 
methods only1. Governments and individuals should work towards the Millennium 
Development Goal target of universal access to reproductive health services by 2015 
through the primary care health system.  
 
Uptake of contraception is variable around the world, varying from 3% in Chad to 
90% in China in women aged 15 – 49 who are married or in a union2. Uptake is high 
in the UK, but methods used are still predominantly pill and condom3. Despite the 
advent of long-acting reversible contraceptive (LARC) methods4, these remain 
minority methods: for example implants were used by only 1% of women aged 16 – 
49 in Britain in 20063. Use of any method of contraception, regardless of its degree of 
effectiveness, is better than using no method. But there are large differences in 
effectiveness between the methods: for instance a 300-fold difference between 
typical use failure rates of male condom and subdermal implant5. Simultaneous use 
of methods where one is a barrier method dramatically lowers the risk of unintended 
pregnancy as well as giving sexually transmitted infection (STI) protection, known as 
dual protection. Most women and men still perceive contraceptive choice as a matter 
of finding the ‘least worst’ option, balancing effectiveness and ease of use against 
perceptions and expectations of adverse effects and health risks6.  
 
Many men are willing to take on the side effects and health risks of contraceptive 
use7. A cross cultural survey found that women felt the contraceptive burden too 
frequently falls to them and they welcomed the availability of a reversible male 
contraceptive which they would trust their partners to take8. 
 
 
Oral contraception 
Newer progestogens9;10 have been used in combined pills: dienogest, nomegestrol 
and drosperinone. All three progestogens have antiandrogenic activity; drospirenone 
has antimineralocorticoid activity. Newer progestogens are being produced in order 
to develop novel positive attributes, enhance positive attributes of existing 
progestogens or to reduce or eliminate undesirable attributes. 
 
 
Dosage of both oestrogen and progestogen has been markedly reduced in recent 
years. Hitherto, ethinylestradiol (EE) has been the main oestrogen used in combined 
pills.  Further work is being done on the use of estradiol (E2) in the combined pill; 
previous attempts had been thwarted by poor cycle control. The rationale for this is 
that a natural steroid would be expected to be less thrombogenic than synthetic 
oestrogens11 and less likely to increase breast cancer risk. An E2 / drospirenone 
combination is being studied in both monophasic and triphasic formulations in 
Germany with respect to cycle control and safety. E2 has been combined with 
dienogest in a quadriphasic formulation. This product has been shown to provide 
efficient ovulation inhibition12. When compared with a 20mcg levonorgestrel (LNG) 
pill in a randomised controlled trial (RCT), cycle control and side effect profile was as 
good as the LNG pill13. E2 has also been combined with nomegestrol; a trial in the 
Netherlands investigating ovarian function which compares E2 / nomegestrol with EE 
/ drospirenone has been completed. Recently, estetrol (E4) a steroid produced by the 
human fetal liver has been studied. E4 is about 18 times less potent than EE, so 
fewer adverse effects would be predicted. Preliminary work on combinations with 
progesterone or desogestrel has been undertaken14.  There is a possibility that E4 
might be protective against breast cancer; it is classified as a natural selective 
oestrogen receptor modulator. 
 
Other types of work on combined pills have perhaps been less original but 
nevertheless have the potential for considerable impact on women’s lives. Extended 
use of the combined pill has become widespread; running several or all packets 
together reduces bleeding days and menstrual cycle-related symptoms15. When used 
continuously for one year, 18% of women achieve amenorrhoea by three months of 
use and 88% by 10 months16. Bleeding is significantly decreased in continuous users 
compared to cyclical users, with an average of three days in cycles 1 to 3 (vs 10 
days, p<.001) and 0 days for cycles 10 to 12 (vs. 9 days, p<.001).  
 
Formulations of 30 mcg of EE and 150mcg of LNG with 84 pills per packet have 
become available, giving a 91-day cycle17. Sixty per cent of women using a 
monophasic formulation containing EE 20mcg and LNG 90mcg with 28 pills in a 
packet, reported amenorrhoea within one year18. It has also been shown that 
shortening the pill-free interval below seven days results in more effective ovarian 
suppression19: combined pills have become available with 24 pills per packet20;21.   
 
Mifepristone is a selective progesterone receptor modulator (PRM) or 
antiprogestogen. PRMs block receptors in the ovary, inhibit the luteinising hormone 
surge and have a powerful endometrial effect. Mifepristone has been studied in a 
phase-2 trial at a daily dose of 5mg compared to an LNG progestogen-only pill22. It 
was shown to be an effective pill with a better bleeding pattern than the progestogen-
only pill. More women were amenorrhoeic while taking mifepristone than 
progestogen-only pill (49 vs 0% p<.001) and fewer women bled or spotted for more 
than five days per month (4 vs 39% p<.001). There were no pregnancies in 356 
months of exposure in women who used only mifepristone for contraception. In a 
Chinese pilot study, once weekly mifepristone at a dose of 25mg showed potential as 
an oral contraceptive pill23. Among 76 women, no pregnancies occurred in 456 
cycles. During the six study cycles, there was a persistent trend toward fewer 
bleeding days and more amenorrhoea. 
 
Another PRM, VA2914, has been piloted as a daily pill24. Forty-six women took this 
for 84 days and ovulation was suppressed in 80% of women without inducing hypo-
oestrogenism. 
 
The development of oestrogen-free oral contraception has significant advantages in 
relation to acceptability and safety. Many women prefer to have either predictable 
bleeding less often than once a month or not to bleed at all25;26. Amenorrhoea during 
mifepristone use is not accompanied by hypo-oestrogenism and there are theoretical 
reasons for thinking that breast cancer risk may be reduced. 
 
 
Emergency contraception 
The combined oestrogen-progestogen regimen was superseded by the progestogen-
only method. The latter has now been combined into one dose. Mifepristone has 
been used in trials for emergency contraception since the early 1990s. Mifepristone 
has just as good efficacy as emergency contraception at a dose of 10mg as at a 
dose of 600mg27. Mifepristone has effectiveness equivalent to LNG 1500mcg when 
used as hormonal emergency contraception28. At present no pharmaceutical 
company wants to pursue marketing for this purpose because of the political 
connotations of its abortifacient effect. In addition, further toxicology testing would be 
needed in order to obtain a licence for use as long-term contraception. 
 
Another PRM, CDB-2914, not known to have abortifacient properties has been 
shown in an RCT to have comparable efficacy to LNG29. Although PRMs have 
endometrial inhibitory activity, this is probably not a significant mechanism of action 
at the low doses used for emergency contraception30. Thus, all methods of 
emergency contraception investigated so far have as their main mechanism of action 
either blockade or delay of ovulation. This raises the point that effectiveness of 
currently available hormonal emergency contraception may be inferior in the luteal 
phase; there is a suggestion that this is so for LNG31. 
 
It has also been shown that meloxicam, a cox-2 inhibitor, can prevent rupture of the 
dominant follicle even after the ovulatory process has been triggered by the 
luteinising hormone surge and so its addition to LNG might improve the efficacy of 
LNG emergency contraception32. A similar delay in follicular rupture has been found 
using rofecoxib33. 
 
 
Injectable contraception 
Depot medroxyprogesterone acetate (DMPA) has been licensed for long term use in 
the UK since 1982. Stimulated by reports of a possible negative effect on bone 
health34, micronised subcutaneous medroxyprogesterone acetate 104mg/ 0.65mL 
has been produced, which is a 30% dose reduction compared to the standard 
formulation. This formulation has a slower rate of absorption and lower peak serum 
levels than intramuscular DMPA and is given at the same interval. Two large phase-3 
non-comparative trials of subcutaneous DMPA have shown high effectiveness and a 
good tolerability profile. Amenorrhoea rates of 55% at 12 months were found with 
subcutaneous DMPA, compared to about 50% with the intramuscular formulation35. 
There have been no published studies so far of subjects using self-injection of 
subcutaneous DMPA36. 
 
Two combined products, both given monthly, have been developed by the World 
Health Organization (WHO). These injectables are now available in many countries 
after extensive trials in South America and China from the 1960s onwards. They both 
add E2 to existing injectable progestogens. The first product is medroxyprogesterone 
acetate 25mg with estradiol cypionate 5mg and the second is norethisterone 
enanthate 50mg with estradiol valerate. Compared to progestogen-only injectables, 
combined injectables disturb bleeding patterns less37 and allow earlier return to 
ovulation after discontinuation38. Bleeding patterns are similar to the combined pill, 
patch or ring. Effectiveness has been shown to be good in studies of everyday use39.  
Pilot studies show that self-injection of monthly injectables is feasible40. 
 
 Vaginal rings 
Delivery of sex steroids via the vaginal route offers several advantages: steroid 
absorption through the vaginal epithelium is rapid, technology allows a constant 
release rate, the method is under the woman’s control and she can remove the ring 
for sex for up to 2 hours. Problems associated with first-pass metabolism and with 
reduced hormone absorption due to gastrointestinal problems are avoided. The use 
of safe and pliable polydimethylsiloxane carriers and the development of hormone-
containing controlled-release polymers have permitted the manufacture of rings that 
can release hormone for up to one year41. All vaginal rings come within the definition 
of long-acting reversible contraceptives, that is administration once per cycle or less 
often4. Acceptability is high among self-selected women taking part in trials, with 
many women changing their minds about which method of contraception they 
perceive to be best, from the combined pill to the combined ring, after a few cycles of 
use42.   
 
The first combined ring to be widely introduced releases 120mcg etonogestrel and 
15mcg EE / day from an ethylene vinyl acetate (EVA) copolymer ring. Women use a 
ring for three weeks followed by a ring-free week during which time they have a 
withdrawal bleed. A new ring is needed for each four-week cycle. Steady state 
hormone release is achieved within three days of insertion. Continuous serum 
hormone levels are achieved with ring use, avoiding the peaks and troughs seen with 
the combined pill. Systemic exposure to EE has been shown to be lower for the 
combined etonogestrel ring than for both the transdermal patch and a 30mcg pill43.  
Two comparative trials showed high efficacy no different from the combined pill, 
especially when adherence is good44;45. Evidence from both clinical studies and 
clinical experience programmes shows better cycle control than with the combined 
pill46-49. The ring can however cause leucorrhoea, vaginal discomfort, vaginitis and 
ring-related events comprising foreign body sensation, coital problems and 
expulsion44;45.     
 
Nestorone rings have undergone preliminary investigation by the Population 
Council41. Nestorone (formerly known as ST-1435) is ineffective orally, but due to its 
high progestogenic potency when given systemically, low doses are sufficient for 
contraceptive efficacy. Rings releasing a combination of nestorone9;10 at a dose of 
150 or 200mcg / day with EE 15 or 20mcg / day are effective for 12 months and so 
are more cost effective. Phase-3 trials are ongoing. 
 
Progestogen-only vaginal rings are less effective than combined rings but have a 
particular application in lactating women as they are oestrogen-free. A ring releasing 
progesterone 10mg / day can be used for up to four months; it is on the market in 
Chile and Peru50. Rings using nestorone are particularly apposite due to rapid 
inactivation when taken orally and so the suckling baby cannot possibly be affected9. 
Nestorone-releasing rings are effective for up to one year51.   
 
In view of the powerful antiovulatory effect of nestorone, twice that of LNG, a phase-1 
study was conducted into the potential of the nestorone combined ring for use as 
emergency contraception in women not at risk of pregnancy52. Judging by ultrasound 
scanning and hormonal profiles, the ring appears to be more effective in disrupting 
ovulation when given in the follicular phase and ovulation was absent after the ring 
had been in situ for seven days. Like the copper intrauterine device (IUD), this 
method could be used as ongoing contraception too. 
 
The Population Council has started investigating the possibility of using the PRM, 
CDB-2914, in a vaginal ring. 
  
Subdermal implants 
Implant technology has been improved considerably. Pharmacokinetics approaching 
zero-order release is now possible; this means that the release is constant over time 
and serum levels are steady. The original LNG implant had the disadvantage of 
comprising six capsules which made insertion and removal lengthy and sometimes 
difficult and so local complications more likely. The capsules were hollow polymer 
tubes filled with free steroid crystals and quite easily torn or divided by forceps or 
scalpel. Newer systems consist of either one or two implants and these are now 
usually solid rods filled with a mixture of steroid crystals and polymer which are much 
more robust, but still flexible. 
 
Contraceptive implants are highly effective4, higher even than vasectomy5. Bleeding 
disturbances remain the single most problematic side effect of implants and the 
newer implants are no different in this respect. 
 
LNG implants are now available in the form of two silastic rods releasing around 
50mcg / day per rod and lasting for five years53. Single-rod etonogestrel (3-keto 
desogestrel) in EVA polymer implants give an initial release rate of about 60mcg / 
day which maintains serum levels well above those needed to inhibit ovulation 
(90pg/mL) for three years54. They are inserted using a disposable applicator. A trial is 
in progress to evaluate a modified etonogestrel implant applicator together with a 
radio-opaque rod; the latter would assist in the event of a difficult removal. 
 
A nestorone implant in the form of a single rod releases steroid from a silicone matrix 
core and has completed phase-2 trials. This implant provides effective contraception 
for two years and has higher acceptance by lactating women who have a more 
favourable bleeding pattern than by those women who do not breast feed55.  
 
Nomegestrol acetate9;10 has been developed in Monaco. It is a potent progestogen, 
exerting a strong effect on the endometrium. Release of about 1000mcg / day from a 
one-year single silastic rod inhibits ovulation effectively56. A multicentre trial in more 
than 1500 women showed a low pregnancy rate and a discontinuation rate of only 
16% at one year. However, there is no plan to commercialise this product. 
   
Biodegradable implants have the advantage of not needing removal, so that the 
possibility of difficult removals is eliminated. LNG has been studied in a phase-2 trial 
as a single capsule composed of the polymer caprolactone over a period of one 
year57. The release of LNG from caprolactone is ten times faster than from the 
silastic in the original implant, allowing a big decrease in size of implant. 
Norethisterone 85% with cholesterol 15% mixed by a heat fusion technique has been 
studied in the form of four or five pellet systems58. 
 
 
Transdermal administration 
With the successful development of matrix technology it has been possible to deliver 
both EE and progestogens through the skin. Norgestimate and its active metabolite 
norelgestromin can be delivered through a transdermal patch, remaining active for 
seven days. A combined patch which releases EE 20mcg / day and norelgestromin 
150mcg / day is now widely available. The patch comprises three layers: an outer 
protective layer of polyester, a medicated adhesive middle layer and a clear polyester 
release liner which is removed just before application. Adherence to the regimen of 
use is better with the patch than with the combined pill, especially in teenagers59.  
 
Systemic exposure to EE is higher with the patch than with a 30mcg pill, despite the 
fact that it releases less EE than the pill43. Effectiveness is as good as the combined 
pill overall, but not in those who weigh more than 90kg60. Breakthrough bleeding and 
mastalgia are more common in cycles 1 and 2 with the patch than with the combined 
pill but thereafter there is no difference59. Three per cent of subjects discontinue the 
patch due to skin reactions59.   
 
Another patch is being developed: this patch releases 50mcg / day of gestodene and 
18mcg of EE and was shown to suppress ovulation in all 199 subjects in a study over 
two cycles61.   
 
Nestorone has also undergone preliminary evaluation in the form of both a gel62 and 
a spray63 . In trials with the gel, mean serum levels of 150pmol/L were observed, 
achieving 83% ovulation suppresssion. The Metered Dose Transdermal System® 
(Acrux Ltd, Melbourne, Australia) is a precisely engineered spray that is capable of 
delivering drugs to the skin surface from they can be rapidly absorbed into the 
stratum corneum which acts as a drug reservoir. Steady state levels of nestorone 
were shown to be achievable with a single daily application of this spray. The mean 
serum level was 391 pmol/L after five days. This is above the level of 250 pmol/L 
needed to suppress ovulation in at least 98% of subjects. 
 
 
Intrauterine devices 
Extensive experience from trials and evidence from systematic reviews has shown 
the TCu380S IUD and the LNG intrauterine system (IUS) to be the most effective 
intrauterine devices developed so far64. As the TCu380S and TCu380A can remain in 
place for up to ten years, their cost effectiveness is particularly high64. Sivin has 
suggested that such devices can retain their efficacy for up to 20 years65. A 
frameless device, the GyneFix® (Contrel, Ghent, Belgium), has been found to have 
comparable effectiveness to the TCu380A66, but the effectiveness of the frameless 
device may be compromised by a higher rate of expulsion. Effectiveness of copper 
IUDs is almost as good as female sterilisation and of the IUS better than female 
sterilisation5. 
 
The development of frameless intrauterine devices has been pursued because 
plastic frames increase blood loss and pain. These devices have a very different 
insertion mechanism which requires specific training and achievement of a high level 
of operator skill; performance of frameless devices inserted by those with less 
experience is not so good. GyneFix® consists of six copper sleeves threaded on a 
length of polypropylene suture material. A knot at the proximal end is placed in the 
fundal myometrium, so anchoring the device. Long term efficacy has been 
demonstrated in a randomised comparative WHO trial67.  
  
The LNG-IUS is a now well-established method that for some time has been the only 
device of its type. Other designs have now been developed. Femilis™ (Contrel, 
Ghent, Belgium) has shorter side arms than the original LNG-IUS. Initial studies 
show good clinical performance68. Insertion is by a simple push-in technique, as with 
a Multiload, and the device is well accepted by nulliparae. There are no comparative 
effectiveness studies. FibroPlant® (Contrel, Ghent, Belgium) is a frameless 
intrauterine system with a LNG-releasing EVA delivery system69. Two versions are 
being developed, releasing 14 and 20mcg LNG / day respectively. These IUSs have 
a lifespan of five years. A metal clip is placed 1 cm from the anchoring knot which 
locates the device on ultrasound or X-ray. FibroPlant® is suitable for insertion into 
uteri of any shape or size70. There are as yet no published data on the contraceptive 
efficacy of this device. 
 
The Population Council has started to investigate the possibility of using the PRM, 
CDB-2914, in an IUS. 
 
 
Spermicides 
In view of the increase in incidence of STIs and HIV, much effort has been put into 
the development of spermicides that have additional microbicidal properties. The 
long-used spermicide nonoxinol-9 (N-9) needs to be replaced for two reasons. First, 
there is no evidence to show it aids efficacy with condoms71. Second, we now know 
that its surfactant effect can damage lower genital tract epithelial surfaces and 
thereby possibly increase the risk of acquisition of infections, including HIV72. As well 
as research into spermicides with microbicidal activity, there has also been intensive 
activity identifying pure microbicides to protect those wanting to achieve pregnancy. 
Of the former category, two preparations reached the stage of clinical trials for 
pregnancy prevention. C31G or Savvy (Biosyn, Philapdelphia, PA, USA) is a 
surfactant which has a satisfactory safety and side effect profile73. A phase-3 
multicentre RCT of C31G compared to N-9 gel is under way in the USA to investigate 
its efficacy, safety and acceptability. Cellulose sulfate (Ushercell™: Polydex 
Pharmaceuticals Ltd, Toronto, ON, Canada) is a polyanion that inhibits 
hyaluronidase, induces acrosomal loss and inhibits cervical mucus penetration. In 
2007, two phase-3 HIV prevention trials of cellulose sulfate were halted because in 
one of the trials a trend had been found toward increased HIV risk74. A phase-2 
contraceptive efficacy study of cellulose sulfate gel conducted in Los Angeles has yet 
to be reported on. A phase-1 study of the spermicide ACIDFORM applied once daily 
showed it to be a safe product75. A phase-1 study of polystyrene sulfonate gel 
showed a safety profile comparable with N-976.     
 
A phase-1 study has been carried out of a gel composed of polyoxyethylene-
polyoxypropylene block copolymer with the microbicide 2% sodium lauryl sulfate77. 
This is applied inside the vagina and acts as both a physical and a chemical barrier. 
The product was imperceptible to all male partners in the study, potentially 
empowering women whose partners will not use condoms. A large phase-3 RCT 
showed that an acid buffering gel, BufferGel, used with a diaphragm was as effective 
as use with N-9 spermicide78. BufferGel is a non-surfactant spermicide which 
reinforces normal vaginal acidity to inactivate both sperm and acid-sensitive sexually 
transmitted pathogens. The 6-month pregnancy rate was 10.1% for BufferGel and 
12.3% for N-9 users. 
 
Finally, a highly innovative pilot study has examined the vaginal administration of 
LNG in Carraguard® gel (Population Council, New York, USA) as a potential 
emergency contraceptive with microbicidal properties79. A single vaginal 
administration of 750mcg LNG in CARRA gel in the late follicular phase was found to 
be effective in interfering with ovulation. This therefore is a promising method for use 
as an emergency contraceptive method for occasional use and has the potential for 
providing dual protection when used before sex thereby putting women more in 
control. The microbicidal properties of CARRA gel have yet to be demonstrated, but 
even if found not to be effective, the principle is established and another microbicide 
could be substituted. 
 
 
Male barrier methods 
Alternative materials to latex rubber have been developed. These include 
polyurethane and styrene ethylene butylene styrene (SEBS). Condoms made with 
these materials have two advantages over latex condoms: a longer shelf-life and the 
ability to be used in the presence of oil-based lubricants. Synthetic non-latex 
condoms have a high acceptability and despite being more liable to split or slip off, 
most are as effective in preventing pregnancy as latex condoms80.   
 
 
Female barrier methods 
Since the introduction of the original polyurethane female condom (FC1) in 1992, 
there have been a number of other products tested which incorporate different 
designs and materials with cost reduction as a major driver. The FC2 female condom 
is made from synthetic latex which is softer than polyurethane and is manufactured 
by a dipping process which is cheaper than the welding used in the original type81. 
The VA feminine condom (also known as the Reddy condom and V-Amour) contains 
a soft sponge to hold it in place inside the vagina rather than a ring; it has a higher 
acceptability than the FC182. The Program for Approved Technology in Health 
(PATH) has developed a woman’s condom which consists of a dissolvable capsule 
intended the make insertion easier, a polyurethane condom pouch and a soft outer 
ring allowing for a nearly universal fit. Once inserted, sections of urethane foam on 
the condom pouch allow the condom to cling lightly to the vaginal walls so that it 
does not move during use; acceptability studies are promising83. 
 
The SILCS diaphragm is being developed by PATH in an iterative process based on 
a needs assessment and subsequent feedback from users and clinicians. It is a 
single-size, non-latex diaphragm with a polymer spring. It fits most women without 
assessment by a health care professional, appears to be more comfortable than 
existing metal spring devices and can be used with either a spermicide or lubricant. 
Magnetic resonance imaging in six subjects showed that the diaphragm covered the 
cervix in all cases and was not dislodged during simulated sex84. A phase-1 study of 
the SILCS diaphragm examined use with either N-9 gel or lubricant only. A reduction 
in the average number of progressively motile sperm per high power field in the 
cervical mucus from a baseline of 12.5 to zero was seen when the diaphragm was 
used with N-985. It has now entered phase-3 trials with randomisation to SILCS 
diaphragm used with BufferGel or SILCS used with 2% N-9 gel. 
 
The effectiveness of the FC1 is lower than that of male condoms5. With all the newer 
female barrier methods, there is a general dearth of efficacy data. 
 
 
Male hormonal methods 
After two decades of research, there is still no hormonal method for men. Work has 
focused on hormones that will suppress follicle stimulating hormone and luteinising 
hormone. Because lack of luteinising hormone leads to atrophy of Leydig cells and 
testosterone deficiency, exogenous testosterone needs to be added to any regimen. 
Progress has been painfully slow in this area of research partly because of difficulty 
finding an appropriate testosterone formulation. To this day, testosterone has to be 
administered by injection or implants; testosterone in the form of tablets or patches 
suppresses sperm less effectively.  
 
The most promising regimens are combinations of testosterone with an oral 
progestogen or progestogen implant86. No combination so far has resulted in 95% 
azoospermia. Due to these small proportions of men who are resistant to hormonal 
suppression, semen analysis would be needed to identify these individuals if a 
product were to be launched.    
 
In multicentre male hormonal trials, it was noted that Asian men respond to 
exogenous androgens with or without progestogens with more suppression of 
spermatogenesis than non-Asians86. Postulated explanations for this have been a 
more sensitive hypothalamo-pituitary axis, lower testis volume or higher basal 
apoptotic rate of germ cells in Asian men. Therefore, it is likely that an ethnic or 
geographical variation exists in the testicular responsiveness to gonadotrophin 
suppression by exogenous androgens and/or progestogens. Androgen alone 
contraceptive regimens may be feasible and effective in Asian men, but not in non-
Asian men. 
 
Trials in men have been characterised by low numbers of subjects mainly due to low 
levels of funding. It is disappointing that both pharmaceutical companies that have 
been funding male hormonal methods have decided to withdraw from this field of 
research87. Reasons for this decision would appear to be perceived poor profitability 
in the context of a shrinking global market and the possibility of legal suit from men 
for whom the method fails. Nevertheless, there is still support from WHO and 
Contraceptive Research and Development Program. 
 
 
Vaccines 
Despite extensive efforts, the quest for a contraceptive vaccine has been largely 
unsuccessful so far88. Only one vaccine has gone through phase-2 trials, an anti-
human chorionic gonadotrophin vaccine89. This vaccine gives contraceptive 
protection to some women, but it generates above protective threshold titres in only 
60 – 80% of women.  
 
 
Female sterilisation 
Mechanical devices such as plugs and thermal occlusion have been investigated with 
limited success and some adverse effects. Two so-called hybrid methods have been 
much more successful. 
 
Essure® (Conceptus Inc, San Carlos, CA, USA) is a metallic and fibre microcoil 
device inserted through the ostia of the Fallopian tubes using a 5-French gauge 
hysteroscope. The inner coil is stainless steel and the outer coil nickel titanium alloy. 
Woven throughout the inner coil are polyethylene terephthalate fibres. The device is 
delivered into the tube in a tightly wound position. When in situ the device is released 
so that the rapidly expanding outer coil fills the tubal lumen, anchoring the device. 
Fibrosis occurs into and around the microcoil, providing an irreversible method. 
Specific training in its insertion is necessary. Placement has to be confirmed, usually 
by X-ray or ultrasound imaging three months after the procedure. Placement failure 
occurs in about 6% of cases90. In women with correctly placed devices, bilateral tubal 
occlusion is demonstrated in 99.5% of women at 12 months. A pregnancy rate of 1.2 
per 1000 has been reported to the device manufacturer in an analysis of 64 
pregnancies out of an estimated 50 000 procedures carried out between 1997 and 
200591. The procedure can be performed in a treatment room setting, with no need 
for operating theatre facilities92. However, UK National Institute for Health and 
Clinical Excellence guidance is still that this procedure should only be performed with 
special arrangements for consent and for audit and research93. In a recent case 
series report, three tubal perforations were described in 143 consecutive insertions94. 
 Adiana® (Hologic Inc, Bedford, MA, USA) is a two-step procedure comprising 
controlled thermal damage of the endosalpinx followed by insertion of a 
biocompatible matrix plug within the tubal lumen. Results in trials are encouraging95. 
 
Women need a full explanation about hybrid methods regarding their complete 
irreversibility but their greater safety, as the abdomen is not entered. 
 
 
Male sterilisation 
Reversible inhibition of sperm under guidance (RISUG) is a clear polymer gel made 
of styrene maleic anhydride mixed with dimethyl sulfoxide which has been developed 
in India. RISUG is injected into the vas and then solidifies; it appears to cause partial 
obstruction of the vas while also causing the membranes of passing sperm to 
rupture. Phase-2 trials show that users have azoospermia or non-motile sperm for at 
least one year96. Further toxicology studies are awaited. 
 
The intra vas device (Shepherd Medical, Minneapolis, MN, USA) is implanted into the 
vas. It consists of two flexible silicone plugs per vas; these are joined by a thread 
which remains outside the vas that is used to remove the device. The method is 
slightly less likely to cause azoospermia than no-scapel vasectomy but delayed 
complications are less frequent97.    
 
The VasClip (VasClip, Roseville, MN, USA) is a small polymeric clip applied to the 
vas. In a phase-2 study, 116 of 119 subjects were azoospermic at 10 – 14 months 
after the procedure98. Sperm granuloma formation incidence was low and 
acceptability high. 
 
  
Conclusions 
 
There are more than a dozen existing methods of contraception, all except two 
designed for women. New methods rely on varying existing technology. The 
development of male hormonal methods has been set back by withdrawal of 
pharmaceutical company support. One has to question the philosophy of the 
pharmaceutical industry in not comprehensively supporting research in 
contraception, which can do so much to promote reproductive rights and to relieve 
suffering of millions of women and their families worldwide. 
 
Although some new oestrogen and progestogen hormones have been synthesised, 
greater progress has been made in developing new delivery systems. Hormones can 
now be delivered via six different routes: oral, injectable, implantable, vaginal, 
transdermal and intrauterine. The development of hormone-containing controlled –
release polymers has allowed steady hormone levels to be maintained for several 
years.  
 
Mifepristone has great potential as an oral contraceptive and emergency 
contraceptive agent, but it would appear that industry is unlikely to invest in this as 
opposition from the public and politicians would be likely to undermine product 
development. A possible solution to this is the development of PRMs without 
abortifacient properties. 
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